172 related articles for article (PubMed ID: 25762344)
1. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs.
Liu Z; Wei P; Yang Y; Cui W; Cao B; Tan C; Yu B; Bi R; Xia K; Chen W; Wang Y; Zhang Y; Du X; Zhou X
Clin Cancer Res; 2015 Apr; 21(7):1752-63. PubMed ID: 25762344
[TBL] [Abstract][Full Text] [Related]
2. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
3. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
6. BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells.
Yang W; Zhao S; Wu B; Xu J; Wu Z; Guo J; Zeng R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1279-1288. PubMed ID: 31549215
[TBL] [Abstract][Full Text] [Related]
7. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
8. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
Liu Y; Tan J; Ou S; Chen J; Chen L
Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
[TBL] [Abstract][Full Text] [Related]
9. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
10. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling.
Takeuchi H; Kim J; Fujimoto A; Umetani N; Mori T; Bilchik A; Turner R; Tran A; Kuo C; Hoon DS
Clin Cancer Res; 2005 Nov; 11(21):7621-8. PubMed ID: 16278380
[TBL] [Abstract][Full Text] [Related]
11. m
Xie JW; Huang XB; Chen QY; Ma YB; Zhao YJ; Liu LC; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Zheng CH; Huang CM; Li P
Mol Cancer; 2020 Jul; 19(1):114. PubMed ID: 32650804
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway.
Matsui S; Osada S; Tomita H; Komori S; Mori R; Sanada Y; Takahashi T; Yamaguchi K; Yoshida K
Int J Oncol; 2010 Aug; 37(2):289-97. PubMed ID: 20596656
[TBL] [Abstract][Full Text] [Related]
13. CREB5 promotes invasiveness and metastasis in colorectal cancer by directly activating MET.
Wang S; Qiu J; Liu L; Su C; Qi L; Huang C; Chen X; Zhang Y; Ye Y; Ding Y; Liang L; Liao W
J Exp Clin Cancer Res; 2020 Aug; 39(1):168. PubMed ID: 32843066
[TBL] [Abstract][Full Text] [Related]
14. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
15. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
16. Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.
Mira A; Morello V; Céspedes MV; Perera T; Comoglio PM; Mangues R; Michieli P
Oncotarget; 2017 Jun; 8(24):38193-38213. PubMed ID: 28445144
[TBL] [Abstract][Full Text] [Related]
17. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
[TBL] [Abstract][Full Text] [Related]
18. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
20. Treatment with Lingqi capsules suppresses colorectal cancer by inhibiting the hepatocyte growth factor/c‑Met signal transduction pathway.
Wang GS; Zhao JL; Li H
Mol Med Rep; 2015 Mar; 11(3):1865-70. PubMed ID: 25373931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
